Business

Third Pole Therapeutics announced that it has raised an additional $25 million in a financing round led by existing investors for continued development of its tankless inhaled nitric oxide (iNO) systems. The company also said… Read more . . .

Aridis Pharmaceuticals announced that it has received an award of $1.9 million from the Bill & Melinda Gates Foundation to fund preclinical development of inhaled monoclonal antibodies against influenza and SARS-CoV-2. Aridis is developing both… Read more . . .

Intranasal vaccine developer Leyden Laboratories has closed a $140M Series B financing led by Casdin Capital and GV, the company said. Proceeds will go toward development of the company’s pipeline, which includes its PanFlu intranasal… Read more . . .

According to Opiant Pharmaceuticals, the company’s contract with the Biomedical Advanced Research and Development Authority (BARDA) has been amended to provide an additional $2.2 million to support activities related to a 505(b)(2) NDA submission for OPNT003 nalmefene… Read more . . .

Aculys Pharma has acquired development and commercialization rights to Neurelis’s Valtoco diazepam nasal spray in Japan, Australia, and other Asia-Pacific countries, including New Zealand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, South Korea, Thailand and… Read more . . .

Glenmark Pharmaceuticals announced that Lotus International, a wholly owned subsidiary of Lotus Pharmaceutical, has acquired the rights to commercialize Ryaltris olopatadine hydrochloride / mometasone furoate nasal spray in Singapore, Hong Kong and Vietnam. Lotus will make… Read more . . .

According to Pneumagen, the company has closed a £3.8 million funding round led by Thairm Bio and Scottish Enterprise, with proceeds intended to fund GMP manufacturing and Phase 2 development of its Neumifil carbohydrate binding… Read more . . .

Australian biotech Medlab Clinical said that it has received a grant from the New South Wales government for development of a proof-of-concept intranasal vaccine based on its NanoCelle “sub-micron delivery platform” technology. The company added… Read more . . .